The lads jetted off to sunny Innsbruck in Austria to get you updates on the latest bone research. We talked to Xenia Goldberg about bone reversal cells and friend of the podcast Kassim Javaid about his highlights of ECTS 2025.

The lads jetted off to sunny Innsbruck in Austria to get you updates on the latest bone research. We talked to three wonderful guests including Morten Svarer Hansen discussing weight loss medicines, Jamie Rowe explaining the molecular structure or bone and Friederike Shulte talking about MPA models.

The lads jetted off to sunny Innsbruck in Austria to get you updates on the latest bone research. We talked to John Carey about the best way to use DEXA in clinics and Mone Ziadi about a new treatment for early menopause.

The lads jetted off to sunny Innsbruck in Austria to get you updates on the latest bone research. We talked to Giovanni Adami about combining and sequencing bone medicines and the possibilities for improving osteoporosis management using AI. We also spoke to Claus-Christian Gluer about a new fracture risk prediction tool called Hive.

The lads talked to Prof Ken Poole about vertebral fractures. Ken explains that vertebral fractures should be never events because of effective treatments that patients can take. We also discuss Martha's law a patient safety initiative in the NHS that allows patients and their families to request a rapid review if they are concerned about their condition.

https://www.england.nhs.uk/patient-safety/marthas-rule/

ken Poole is Professor of Metabolic Bone Disease University of Cambridge. Ken applies novel imaging techniques to investigate bone diseases. He also runs NHS clinical services for metabolic bone diseases and specialised rheumatology needs. One key project is the PHOENIX study which aims to improve the diagnosis of vertebral fractures using routine CT scanning.

The lads talked to Dr Elena Tsourdi about personalised care for osteoporosis patients. Elena is working as the Senior Consultant at the Department for Metabolic Bone Diseases, with a focus on secondary osteoporosis and rare bone diseases. We had a fascinating chat about how doctors and patients can build trust and prescribe medicines to get the best outcomes for individual patients.

The lads talked to Professor Roland Baron from Harvard University. Roland has played a key role in characterising bone signalling pathways that govern bone formation and contributed to developing new treatments that increase cell signalling to improve bone mass.

Roland is a co-founder and chair of the International Federation of Musculoskeletal Research Societies supporting our community and helping young scientists from the entire world to develop and support people living with osteoporosis.

The lads talked to each other about the exciting news that the National Institute for Health and Care Excellence (Nice) announced it had approved a new drug, Abaloparatide, for use by the health service. It will be available for use on the NHS in England within three months.